4.7 Article

Design, synthesis, and biological evaluation of novel 2'-methyl-2'-fluoro-6-methyl-7-alkynyl-7-deazapurine nucleoside analogs as anti-Zika virus agents

Journal

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 234, Issue -, Pages -

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2022.114275

Keywords

Zika virus; Anti-ZIKV; 7-Deazapurine; Nucleoside analogs

Funding

  1. China Evergrande Group [SKLAID201805]
  2. open project of State Key Laboratory of Anti-Infective Drug Development [2020GIRHHMS08]

Ask authors/readers for more resources

Zika virus, a mosquito-borne flavivirus, has caused serious medical consequences and complications in recent years. There are currently no specific treatments or vaccines, highlighting the need for new therapies. In this study, a series of novel nucleoside analogs were synthesized and one compound showed potential as an inhibitor of Zika virus replication. This compound may be a promising candidate for future drug discovery.
Zika virus (ZIKV) is a mosquito-borne flavivirus and outbreaks of ZIKV have been reported in Africa, Americas and other parts of the world lately. The ZIKV epidemic has received extensive attention due to its ability to cause serious medical consequences and complications such as microcephaly and Guillain-Barre syndrome in recent years. Up to now, there are no specific treatments or vaccines available for ZIKV infection, which highlights the urgent need for developing new therapies. In this work, we designed and synthesized a series of novel 6-methyl-7-acetylenenyl-7-deazapurine nucleoside analogs as potential inhibitors of ZIKV replication. The biological activities against ZIKV replication were evaluated and the structure-activity relationship (SAR) was also studied. Among the compounds evaluated, nucleoside analog 38 (EC50 = 2.8 +/- 0.8 mu M, EC90 = 6.8 +/- 2.3 mu M) showed the most potent anti-ZIKV activity with low cytotoxicity (CC50 = 54.1 +/- 6.9 mu M) in an A549 based cellular model. The inhibitory activity of 38 was about 5 times more potent than the positive control NITD008. Notably, 38 showed similar inhibition potency against different ZIKV strains (ZG-01 and MR766) in a variety of host cell types including SNB19, A549, Huh7, Vero. In addition, 38 (K-d = 1.87 mu M) has a stronger affinity to ZIKV RNA-dependent RNA polymerase (RdRp) protein than NITD008 (K-d = 3.43 mu M) in the non-phosphorylation assay. These results indicated that compound 38 may serve as a promising candidate in future anti-ZIKV drug discovery. (C) 2022 Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available